Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.

ABSTRACT:

Background

Hetrombopag has been approved for chronic ITP (duration >12 months). However, its efficacy and safety in persistent ITP (duration 3-12 months) remain unexplored.

Objectives

This post-hoc analysis aimed to evaluate the efficacy and safety of hetrombopag in persistent ITP patients and compare outcomes with chronic ITP and overall ITP patients, based on existing clinical data.

Methods

Data were derived from a registration phase Ⅲ trial (NCT03222843), which included a 10-week randomized, double-blind, placebo-controlled treatment period (initial dose: hetrombopag 2.5 mg as HETROM-2.5 group, hetrombopag 5.0 mg as HETROM-5.0 group, or placebo once daily), a 14-week open-label treatment period, a dose tapering to withdrawal period and a 24-week single-arm extensio

SUBMITTER: Mei H 

PROVIDER: S-EPMC12684654 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature